AstraZeneca has announced a historic agreement with President Donald Trump’s administration to lower the cost of prescription medicines for American patients while preserving the nation’s cutting-edge biopharmaceutical innovation.

At a landmark event held at the White House, AstraZeneca CEO Pascal Soriot joined President Trump and senior administration officials to confirm that the company has voluntarily met all requests outlined in the President’s 31 July letter.

Under the agreement, AstraZeneca will introduce a series of measures designed to enable American patients to access medicines at prices equal to those available in wealthy countries. The company will also provide Direct-to-Consumer (DTC) sales to eligible patients with prescriptions for chronic diseases at a discount of up to 80 percent off list prices.

AstraZeneca will participate in the TrumpRx.gov direct purchasing platform, which will allow patients to purchase medicines at a reduced cash price from the company.

In addition, the company has reached an accord with the US Department of Commerce to delay Section 232 tariffs for three years, enabling the company to fully onshore medicines manufacturing so that all of its medicines sold in America are made in America.

The agreement complements AstraZeneca’s recently announced USD 50 billion investment in US manufacturing and R&D over the next five years, which is expected to help deliver USD 80 billion in revenue by 2030, with half projected to come from the US market.

Soriot said, “Every year AstraZeneca treats millions of Americans living with cancer and chronic diseases and, as a result of today’s agreement, many patients will access life-changing medicines at lower prices. This new approach also helps safeguard America’s pioneering role as a global powerhouse in innovation and developing the next generation of medicines. It is now essential other wealthy countries step up their contribution to fund innovation.”

AstraZeneca’s growing commitment to the U.S. is underscored by its largest single manufacturing investment to date, a new facility in Virginia that will support its weight management, metabolic, and antibody drug conjugate (ADC) cancer pipeline. The company will also officially open its expanded Coppell, Texas manufacturing site next week.

Looking ahead, AstraZeneca plans to open a cell therapy manufacturing facility in Rockville, Maryland early next year and a second major R&D centre in Cambridge, Massachusetts in late 2026.   

The US remains AstraZeneca’s largest market by sales and is home to 19 R&D, manufacturing, and commercial sites. In 2025 alone, the company contributed approximately USD 20 billion in value to the American economy.